Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata causes hair loss, has no cure, and various treatments exist.

Finasteride and minoxidil are effective for hair loss, but continued research is needed for better treatments.

Different hair diseases affect people during childbearing years, with treatments ranging from medication to psychological support.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

Hair loss from alopecia areata and androgenetic alopecia can be treated, but more effective and safer treatments are needed.

No single treatment is consistently effective for alopecia areata, and more research is needed.

New treatments for hair loss show promise but need more research to confirm safety and effectiveness.

The document concludes that various childhood hair and nail disorders exist, some may improve on their own, and advances in genetics and immunology could enhance treatment and counseling.

The document concludes that early diagnosis and treatment are key for pediatric hair loss disorders, and addressing the emotional effects on children is important.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

Alopecia areata is an autoimmune condition causing hair loss due to the immune system attacking hair follicles, often influenced by genetics and stress.

Both mouse and rat models are effective for testing alopecia areata treatments.

A girl with Crohn's disease developed hair loss from her medication, which improved with treatment but later returned.

Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.

The document explains hair and nail biology, common hair loss conditions and treatments, oral and genital skin diseases, and the risks and treatments associated with squamous cell carcinoma.

The most common cause of hair loss in children is tinea capitis, followed by alopecia areata and telogen effluvium.

Topical sensitizers have mixed success in treating alopecia areata.

Topical squaric acid dibutylester worsened discoid lupus erythematosus in a patient.

Diphenylcyclopropenone topical immunotherapy is effective for treating alopecia areata, with some side effects.

The document concludes that various hypersensitivity diseases in horses can be diagnosed and treated with methods like immunotherapy and medication, and early aggressive treatment is crucial for severe diseases like equine cutaneous pythiosis.

DNCB helps regrow hair in alopecia areata patients, but safer alternatives are needed.

Inhibiting PLA2 enzymes may help treat inflammatory skin diseases like psoriasis and dermatitis.

A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.

Two plywood factory workers developed contact dermatitis from phenol-formaldehyde resin, a known allergen.

Avoiding dyed wigs and clothing improved severe allergic reactions in a woman treated with diphencyprone.

The document concludes that pregnancy and cancer share immune evasion tactics, but more research is needed before using checkpoint blockade immunotherapy in pregnant cancer patients to avoid harm to the placenta.

Topical immunotherapy for alopecia areata may work by creating immune cell clusters in the skin.

DPCP is effective for treating severe alopecia areata, but relapse is common.

The document concludes that computational models are useful for understanding immune responses and could improve cancer immunotherapy.

Various treatments exist for alopecia areata, but none are completely satisfactory; choice depends on age, disease extent, and preference.